Providers

Dr Matthew Banks is a consultant gastroenterologist at University College London Hospitals (UCLH) where he has been director of endoscopy for 6 years, leading the largest Barrett’s oesophagus centre in the UK. He works privately in Harley Street, The Lister Hospital Chelsea, The London Clinic and Princess Grace Hospitals where he founded a team of gastroenterologist and surgeons- London Gastrointestinal Associates. He was also Director of Endoscopy at Chelsea & Westminster Hospital.

His expertise:

• Heartburn and indigestion
• Barrett’s oesophagus
• Bowel cancer screening and polyp detection
• Constipation & diarrhoea
• Irritable bowel syndrome
• Oesophageal & gastric cancer
• Endoscopy, colonoscopy therapy
• Laser therapy
• Polypectomy
• EMR
• ESD & more.

Dr Siebert is a Clinical Senior Lecturer in Inflammation and Rheumatology at the Institute of Infection, Immunity and Inflammation at the University of Glasgow. He also works as Honorary Consultant Rheumatologist in the Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde where he runs specialist psoriatic arthritis clinics.

Dr Siebert leads the spondyloarthritis and psoriatic arthritis clinical research programme in Glasgow, and leads on a numbers of national and regional investigator led studies. He is also involved in studies investigating underlying disease mechanisms and new therapies in rheumatoid arthritis. He is the current chair of the Arthritis Research UK Progress Review Committee, on the Executive Steering committees of both BRIT-SpA and BRIT-PACT (British SpA and PsA societies, respectively) and member of GRAPPA and ASAS.

Dr Laura Coates joined the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), Oxford in 2017 as an National Institute of Health Research (NIHR) Clinician Scientist to research optimal therapeutic strategies for patients with psoriatic arthritis (PsA).

Laura is establishing a new psoriatic arthritis service in Oxford to see if a more practical version of ‘treat to target’, an approach where a patient’s treatment is increased regularly until a target was achieved can be run successfully in a routine NHS Clinic. Laura developed this approach to the condition when conducting the Tight Control of Psoriatic Arthritis (TICOPA) clinical study, which found that the ‘treat to target’ improves patients’ outcomes.

Laura is also testing different treatment options in an attempt to personalise care. She expects to discover whether patients with mild (PsA) can be treated successfully without more powerful arthritis drugs, and thereby avoid side effects. And also to discover whether patients with a severe form of the condition, do better if they start on stronger arthritis drugs.

Laura completed her rheumatology training and her PhD at the University of Leeds in the Leeds Institute of Rheumatology and Musculoskeletal Medicine. Her PhD focused on the development and validation of the minimal disease activity criteria for PsA, which she established in the TICOPA study.

Laura’s research is clinical and focuses on psoriatic arthritis and the spondyloarthritides including early diagnosis of PsA, development of PsA, specific and validated outcome measures, optimal treatment pathways and strategies in PsA. Laura has developed and validated screening questionnaires to identify PsA. She has experience in outcome measurement, and has been involved in the development and validation of novel clinical and imaging outcome measures.

Laura is the first author of the TICOPA study. This is the first study to address treating to target in PsA, and improved clinical and patient reported outcomes. In 2011 Laura’s publications and their impact was recognized and she was awarded one of eight UK Scopus Young Investigator Awards. In 2012 she obtained the University of Leeds Women of Achievement Award.

Laura is a member of the Steering Committee of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the British Psoriatic Arthritis Consortium (Brit-PACT). She is the first author on the 2015 GRAPPA treatment recommendations for psoriasis and PsA, and is also involved in the GRAPPA/OMERACT (Outcome Measures in Rheumatology) initiative to refine the core set of outcome measures for PsA.

High Oaks Dental welcomes your entire family to our St Albans Dental Practice. High Oaks Dental Practice is one of the best emergency dentistry offering 24-hour dental emergency in St Albans, Hertfordshire and nearby areas. Our team of Dentists in  St Albans brings you the expertise, incorporating technology to offer patients with an optimal dental care in a relaxing environment.
Find the right clinic for Invisible Braces in St Albans, compare prices, read reviews and see before after pictures. Do not hesitate to call us on 0172 789 3430 to book your first appointment.

The London Vaginal Atrophy Clinic offers unique and ideal solution for an effective treatment of vaginal atrophy in London, as well as discomfort, dryness, laxity and painless intercourse treatments in London.

The London Vaginal Atrophy is a Dyspareunia treatment clinic in London providing effective Dyspareunia treatments, a sexual pain disorder felt in the genital area or pelvic.

Hi-tech company that is developing proprietary, flexible microbiosensor integrated computer chips suitable for printing on many surfaces.

These chips which detect certain biomolecules can be linked to smart devices and shared via cloud technology.

SKC’s chips are being developed to detect and measure biological signals and data from humans and then use smart devices to transmit the information for analysis and storage.

These microbiosensor chips are also being developed for use as diagnostic devices for early detection of human diseases as well as pathogens in the food chain from the farm to consumer.

Early applications could include the efficient, accurate, and inexpensive detection of air and waterborne pathogens in restaurants, hospitals, and hotels.

Hello, my name is Pei-Pei and I am a consultant ENT and facial plastic surgeon.

I offer a highly personal and professional approach to beauty therapy, skin care, cosmetic surgery and medical procedures for ENT problems.

I have completed a fellowship by the European Academy of Facial Plastic Surgery and gained specialist training in Europe, London and South Korea.

I was awarded the European Board for Certification in Facial Plastic and Reconstructive Surgery (EBFPRS) which is an exam taken in collaboration with the American Board of Facial Plastic and Reconstructive Surgery.

The procedures I offer include Neurotoxin injection, dermal filler injection, Platelet-rich plasma treatment (PRP), eyelid surgery, nose reshaping surgery (rhinoplasty) and face lifts. I also consult regarding skin care and offer medical grade skin care systems.

I consult in KIMS in Maidstone, and Nuffield Health in Tunbridge Wells.

Dr. Kornberg is an American biochemist and professor of structural biology at Stanford University School of Medicine. In 2006, Dr. Kornberg was awarded the 2006 Nobel Prize in Chemistry for his studies of the molecular basis of eukaryotic transcription. He determined how DNA’s genetic blueprint is read and used to direct the process for protein manufacture. Dr. Kornberg carried out a significant part of the research leading to this prize at the Stanford Synchrotron Radiation Laboratory (SSRL), a Department of Energy (DOE)-supported research facility located at the Stanford Linear Accelerator Center (SLAC).

Prior to joining the faculty at Stanford University School of Medicine, Dr. Kornberg was a postdoctoral research fellow at the Laboratory of Molecular Biology in Cambridge, England. In 1976 he became an Assistant Professor of Biological Chemistry at Harvard Medical School before moving to his current present position at Stanford Medical School in 1978.

Dr. Kornberg also carried out research at the Advanced Light Source, another DOE-funded synchrotron light source located at the Lawrence Berkeley National Laboratory. Dr. Kornberg was the first to create an actual picture of how transcription works at a molecular level in the important group of organisms called eukaryotes (organisms whose cells have a well-defined nucleus). Humans and other mammals are included in this group, as is ordinary yeast. For cells to produce working proteins—a process necessary for life—information stored in DNA must first be transcribed into a form readable by the cell’s internal machinery.

Dr. Kornberg has served as the Chairman of the Scientific Advisory Boards of many companies including Cocrystal Discovery, Inc, ChromaDex Corporation, StemRad, Ltd, Oplon Ltd, and Pacific Biosciences. He has also served as a Board Director for OphthaliX Inc., Protalix BioTherapeutics, Can-Fite BioPharma, Ltd, and Teva PharmaceuticalIndustries, Ltd.

Dr. Kornberg’s studies have provided an understanding at the atomic level of how the process of transcription occurs and also how it is controlled. Because the regulation of transcription underlies all aspects of cellular metabolism, Dr. Kornberg’s research also helps explain how the process sometimes goes awry, leading to birth defects, cancer, and other diseases.

Josh Shachar has been involved in advanced technologies for the Department of Defense for over 20 years. Mr. Shachar has held many executive management positions at high-technology companies dealing directly with the United States Department of Defense.

Mr. Shachar began his professional career in 1981 at ThermoControl, Inc. in Chatsworth, California, as the founder and Vice President of Engineering. This company was acquired by Daily Instrument of Houston, Texas. In 1996, Mr. Shachar served as the Vice President of Engineering at Pastushin Aviation, Inc. In the following year, Mr. Shachar founded and served as the President of Lambda Signatics, Inc., which was later acquired by Shapco Industries.

Mr. Shachar is still the principal owner and founder of numerous high-technology companies including ThermoCouple America LLC, EDEL Engineering Development Corp., and Engineered Magnetics, Inc.

Mr. Shachar is an author of numerous U.S. Patent applications in medical, biometrics and diagnostic applications.

Dr. Thomas Chen is a physician, a board certified neurosurgeon, and the Director of Surgical Neuro-oncology at USC. He is highly recognized for his skills as a neurosurgeon, and is also a tenured Professor of Neurosurgery and Pathology at USC.

Dr. Chen graduated summa cum laude in three years from the University of Illinois at Urbana-Champaign, where he also received Bronze Tablet honors (top 3% of undergraduate students) and was inducted into the Phi Beta Kappa national academic honor society. He then attended the University of California, San Francisco, where he was inducted into the Alpha Omega Alpha national medical honor society. Afterward, he underwent neurosurgery training at the University of Southern California (“USC”).

In order to prepare for his career in neuro-oncology, Dr. Chen also obtained a Ph.D. degree in pathobiology. His thesis was on the role of immunotherapy in malignant brain tumors. He is also a fellowship-trained spine surgeon and one of a few surgical neuro-oncologists in the country who specialize in spine cancer surgery.

Currently, Dr. Chen maintains a busy clinical practice in both surgical neuro-oncology and spine surgery. He heads a research laboratory focused on glioma biology.

Dr. Chen has published extensively on glioma biology and neurosurgery. He is on the editorial board for The Spine Journal and Journal of Neuro-oncology, and is on the review board for Neurosurgery and Journal of Neurosurgery. He is on numerous national neurosurgery committees.